MarketAnalysis市场分析
NYSE:TEVA

Teva Pharmaceutical Industries Limited - NYSE:TEVA - Comprehensive analysis

Free evaluation through quantitative algorithms Teva Pharmaceutical Industries Limited - NYSE:TEVA

Quant Rating

1

Strong Sell

2

Sell

3

Hold

4

Buy

5

Strong Buy


The overall quant rating is not an average of the factor grades listed.Instead, it gives greater weight to the metrics with the strongest predictive value.

Growth-Scoring Model Detail

Name

Fatcor
Percentage

Total Revenue Growth Over Prior Year

4.4

Market

50

Sector

54

Gross Profit Growth Over Prior Year

5.45

Market

48

Sector

55

EBITDA Growth Over Prior Year

2.26

Market

32

Sector

45

EBITA Growth Over Prior Year

4.32

Market

44

Sector

43

EBIT Growth Over Prior Year

6.04

Market

46

Sector

47

Earnings from Cont. Ops. Growth Over Prior Year

0

Market

0

Sector

0

Net Income Growth Over Prior Year

0

Market

0

Sector

0

Normalized Net Income Growth Over Prior Year

31.1

Market

83

Sector

67

Diluted EPS before Extra Growth Over Prior Year

0

Market

0

Sector

0

A/R Growth Over Prior Year

-10.24

Market

11

Sector

15

Inventory Growth Over Prior Year

-25.22

Market

2

Sector

7

PPE Net Growth Over Prior Year

-19.51

Market

3

Sector

23

Total Assets Growth Over Prior Year

-9.55

Market

6

Sector

32

Tangible Book Value Growth Over Prior Year

0

Market

0

Sector

0

Common Equity Growth Over Prior Year

-28.42

Market

4

Sector

21

Cash from Ops. Growth Over Prior Year

-8.85

Market

26

Sector

28

CAPEX Growth Over Prior Year

-5.32

Market

28

Sector

45

Dividend per Share Growth Over Prior Year

0

Market

36

Sector

48

Levered Free Cash Flow Growth Over Prior Year

-20.4

Market

18

Sector

24

Unlevered Free Cash Flow Growth Over Prior Year

-17.5

Market

20

Sector

23

Profitability-Scoring Model Detail

Name

Fatcor
Percentage

Gross Margin %

48.7

Market

59

Sector

49

SG&A Margin %

22.4

Market

70

Sector

35

EBITDA Margin %

26.8

Market

55

Sector

90

EBITA Margin %

23.9

Market

66

Sector

90

EBIT Margin %

20.4

Market

57

Sector

90

Earnings from Cont. Ops Margin %

-11.84

Market

3

Sector

32

Net Income Margin %

-9.91

Market

3

Sector

35

Net Income Avail. for Common Margin %

-9.91

Market

3

Sector

35

Normalized Net Income Margin %

10.97

Market

56

Sector

90

Levered Free Cash Flow Margin %

15.85

Market

68

Sector

88

Unlevered Free Cash Flow Margin %

19.64

Market

73

Sector

90

Return on Assets %

5.09

Market

48

Sector

84

Return on Capital %

8.06

Market

51

Sector

88

Return on Equity %

-28.3

Market

2

Sector

56

Return on Common Equity %

-25.45

Market

2

Sector

57

Total Asset Turnover

0.4

Market

38

Sector

55

Sub-Scoring Model

Valuation
Momentum
Growth
Profitability
80
60
40
20
Valuation: 66
Momentum: 97
Growth: 29
Profitability: 41

Valuation-Scoring Model Detail

Name

Fatcor
Percentage

TEV/LTM Total Revenue

3.06

Market

41

Sector

43

TEV/LTM EBITDA

10.91

Market

29

Sector

38

P/LTM Normalized EPS

19.21

Market

22

Sector

30

P/BV

4.51

Market

60

Sector

69

TEV/LTM Unlevered FCF

23

Market

39

Sector

56

Momentum-Scoring Model Detail

Name

Fatcor
Percentage

1M Price Performance

32.7

Market

100

Sector

90

3M Price Performance

46

Market

98

Sector

80

6M Price Performance

60

Market

96

Sector

71

9M Price Performance

64

Market

96

Sector

76

1Y Price Performance

61

Market

96

Sector

81

Start analyzing Teva Pharmaceutical Industries Limited - NYSE:TEVA with easy-to-understand research reports

Start analyzing Recent popular companies with easy-to-understand research reports